Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:GNLX NASDAQ:SNYR NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.45-2.0%$1.60$1.13▼$2.66$132.07M2.61265,927 shs96,988 shsGNLXGenelux$3.41+6.6%$3.16$1.95▼$5.89$120.88M-0.32124,647 shs38,641 shsSNYRSynergy CHC$3.55-8.0%$3.12$1.19▼$10.00$35.49MN/A48,833 shs123,098 shsTARAProtara Therapeutics$3.19-2.1%$3.12$1.60▼$10.48$125.78M1.42209,946 shs99,408 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-2.03%+0.69%-8.23%+4.32%-17.14%GNLXGenelux+6.56%+2.10%+10.71%+37.50%+63.16%SNYRSynergy CHC-8.03%-2.20%+4.41%+49.16%+11,733.33%TARAProtara Therapeutics-2.15%+2.90%+4.59%0.00%+61.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.9719 of 5 stars3.53.00.00.02.60.00.0GNLXGenelux1.8828 of 5 stars3.62.00.00.03.00.00.0SNYRSynergy CHC4.0858 of 5 stars3.80.00.00.03.93.31.9TARAProtara Therapeutics2.1706 of 5 stars3.61.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00175.86% UpsideGNLXGenelux 3.20Buy$17.75420.53% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00181.69% UpsideTARAProtara Therapeutics 3.17Buy$19.60514.42% UpsideCurrent Analyst Ratings BreakdownLatest SNYR, CGEN, GNLX, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M4.64N/AN/A$0.56 per share2.59GNLXGenelux$10K12,879.57N/AN/A$0.63 per share5.41SNYRSynergy CHC$34.83M0.94$0.24 per share14.51($1.91) per share-1.86TARAProtara TherapeuticsN/AN/AN/AN/A$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%N/AGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%N/ASNYRSynergy CHC$2.12MN/A0.006.02N/AN/A-8.48%12.75%N/ATARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%N/ALatest SNYR, CGEN, GNLX, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SNYRSynergy CHC$0.08$0.17+$0.09$0.17N/AN/A8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.744.74GNLXGeneluxN/A4.184.67SNYRSynergy CHCN/A1.911.62TARAProtara TherapeuticsN/A12.8118.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%GNLXGenelux37.33%SNYRSynergy CHCN/ATARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%GNLXGenelux8.80%SNYRSynergy CHC56.60%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableSNYRSynergy CHC409.19 million3.99 millionN/ATARAProtara Therapeutics3038.58 million35.34 millionOptionableSNYR, CGEN, GNLX, and TARA HeadlinesRecent News About These CompaniesWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13 at 10:02 AM | finance.yahoo.comProtara Therapeutics (NASDAQ:TARA) Announces Quarterly Earnings ResultsAugust 12 at 6:41 PM | marketbeat.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12 at 4:42 AM | msn.comProtara Beats Q2 Loss EstimatesAugust 11, 2025 | aol.comAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comProtara Therapeutics (TARA) to Release Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 25, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Shares Up 11% - Still a Buy?July 22, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30, 2025 | globenewswire.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of DirectorsJune 23, 2025 | quiverquant.comQProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comFThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNYR, CGEN, GNLX, and TARA Company DescriptionsCompugen NASDAQ:CGEN$1.45 -0.03 (-2.03%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 08/14/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Genelux NASDAQ:GNLX$3.41 +0.21 (+6.56%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$3.40 -0.01 (-0.29%) As of 08/14/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Synergy CHC NASDAQ:SNYR$3.55 -0.31 (-8.03%) As of 08/14/2025 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.Protara Therapeutics NASDAQ:TARA$3.19 -0.07 (-2.15%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$3.25 +0.06 (+1.88%) As of 08/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access